Atom Bioscience Names Stanford University Professor Vibeke Strand, M.D., to its Scientific Advisory Board

PRESS RELEASE

Atom Bioscience Names Stanford University Professor Vibeke Strand, M.D., to its Scientific Advisory Board

Dr. Strand has 40 years’ experience in the drug development industry

Jiangsu, China—January 25, 2023 – Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the addition of Vibeke Strand, M.D., a drug development and regulatory expert with 40 years’ experience, to its Scientific Advisory Board. Dr. Strand, a rheumatologist, is an Adjunct Clinical Professor in the Division of Immunology/Rheumatology at Stanford University School of Medicine.

“We are delighted to have Dr. Strand join our Scientific Advisory Board,” said Atom Founder, CEO, President and Chairman William Shi, Ph.D. “Her wide-ranging experience in all phases of drug development will be invaluable as we move our pipeline forward to help chronic gout patients who now have limited effective treatments.”

Atom’s lead product, ABP-671, is an oral, small molecule URAT1 inhibitor for treatment of chronic gout. The drug is designed to reduce excessive levels of uric acid in the blood, a condition called hyperuricemia, which is the cause of gout and its characteristic painful and debilitating flare-ups. In a Phase 2a trial, ABP-671 was well tolerated and reduced uric acid levels below the threshold for hyperuricemia. The company expects to enter a Phase 2b/3 clinical trial soon.

“I am very pleased to be part of the Atom Bioscience team,” said Dr. Strand. “There is an urgent need for more effective therapies for gout. Atom’s data are very encouraging, and I look forward to helping Atom bring this new, promising therapy to market.”

Dr. Strand is an expert in defining regulatory strategies and efficient clinical development programs for novel therapies. She joined the faculty of Stanford School of Medicine in 1993 after serving as associate clinical professor at the University of California, San Francisco, School of Medicine. Her extensive experience in the biotech and pharmaceutical industry includes serving as Senior Director of Clinical Research at Xoma Corporation; Director of Clinical Research and Regulatory Affairs at Applied Immune Sciences; and Head, Section for Anti-Rheumatic and Immunotherapy at Syntex Research: Institute of Clinical Medicine. Prior to that she was in rheumatology subspecialty practice in San Francisco. Subsequently she has served as a consultant in clinical development and regulatory strategy since 1991. She has authored 500 publications and multiple book chapters.

Gout is one of the most common types of inflammatory arthritis affecting more than 55 million people worldwide. The disease has a large and growing patient population in the U.S., Europe, Asia and Latin America. The painful gout flare-ups, concentrated primarily in the joints of lower extremities, occur when uric acid in the blood exceeds levels greater than 7 mg/dL, the threshold for hyperuricemia. Failure to maintain healthy levels of uric acid can cause permanent joint damage as well as other complications such as heart, kidney and eye diseases.

Atom’s Scientific Advisory Board also includes Kenneth Saag, M.D., Professor at the Department of Medicine, Division of Clinical Immunology and Rheumatology at University of Alabama at Birmingham; and N. Lawrence Edwards, M.D., Vice Chairman and Professor, Department of Medicine, University of Florida.

About Atom Bioscience

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., is a fast-growing innovative drug company focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in late stage

clinical development for treatment of chronic gout. For more information please visit: https://atombp.us/.